Longevity & AgingNew Oral Drug SRN-901 Extends Mouse Lifespan by 33% and Cuts Tumor Risk
Seragon Biosciences has published preclinical results showing its oral drug SRN-901 extended median remaining lifespan by 33% in aged mice eating a Western diet, outperforming rapamycin's 21% gain. The drug also reduced the statistical risk of death by 46%, slowed frailty progression by 70%, and cut tumor incidence by over 30%. Molecular analysis showed the drug activated DNA repair, improved energy metabolism, and dialed down inflammation and a key aging-related growth pathway called mTORC1. NMN and NR showed no significant lifespan benefit in the same study. SRN-901 is a multi-compound oral formulation taken daily, positioning it as a broad-spectrum longevity intervention rather than a single-target drug.
